ABSTRACT
ABSTRACT: The aim of this work is to provide a methodology for evaluating the committed effective dose E(50) due to the incorporation of [18F] FDG in the occupationally exposed worker (OEW) of the Cyclotron-PET/CT Laboratory of the Centro de Investigación en Ciencias Atómicas, Nucleares y Moleculares (CICANUM) at Universidad de Costa Rica using in vivo measurements. The measurement system was calibrated to perform in vivo measurements and defined as the corresponding bioassay function for the radiopharmaceutical used. The conversion factor was assessed with a known activity of 18F in the geometry and measurement time established. Among the most relevant results, the measurement parameters and the calibration procedure were defined. A value of 1.73 x 103 Bq/cps for in vivo brain measurements was obtained as a conversion factor. This study provides a methodology, to evaluate the committed effective dose due to the incorporation of 18F-FDG in a radionuclide production and diagnostic center
Subject(s)
Radiation Protection , Occupational Exposure/adverse effects , Cyclotrons/instrumentation , Radiation DosageABSTRACT
Due to interesting therapeutic properties of 177Lu and tumor avidity of tetraphenyl porphyrins (TPPs), 177Lu-tetraphenyl porphyrin was developed as a possible therapeutic compound. 177Lu of 2.6-3 GBq/mg specific activity was obtained by irradiation of natural Lu2O3sample with thermal neutron flux of 4 × 1013 n.cm-2.s-1. Tetraphenyl porphyrin was synthetized and labeled with 177Lu. Radiochemical purity of the complex was studied using Instant thin layer chromatography (ITLC) method. Stability of the complex was checked in final formulation and human serum for 48 h. The biodistribution of the labeled compound in vital organs of wild-type rats was studied up to 7 d. The absorbed dose of each human organ was calculated by medical internal radiation dose (MIRD) method. A detailed comparative pharmacokinetic study was performed for 177Lu cation and [177Lu]-TPP. The complex was prepared with a radiochemical purity: >97±1% and specific activity: 970-1000 MBq/mmol. Biodistribution data and dosimetric results showed that all tissues receive approximately an insignificant absorbed dose due to rapid excretion of the complex through the urinary tract. [177Lu]-TPP can be an interesting tumor targeting agent due to low liver uptake and very low absorbed dose of approximately 0.036 to the total body of human...
Devido às propriedades interessantes do 177Lu e da avidez tumoral das tetrafenil porfirinas (TPP), desenvolveu-se a 177Lu-tetrafenil porfirina como composto terapêutico potencial. 177Lu de atividade específica de 2,6-3 GBq/mg foi obtido por irradiação de amostra de Lu2O3 com fluxo térmico de nêutrons de 4 × 1013 n.cm-2.s-1. Sintetizou-se a tetrafenil porfirina e marcou-se com 177Lu. A pureza radioquímica do complexo foi estudada usando método de Cromatografia Instantânea de Camada Delgada ( ITLC). A estabilidade do complexo foi checada na formulação final e no ser humano por 48 h. A biodistribuição do composto marcado em órgãos vitais de ratos do tipo selvagem foi estudada por mais de 7 dias. A dose absorvida para cada órgão humano foi calculada pelo método da Dose Médica de Radiação Interna (MIRD). Estudo farmacocinético comparativo detalhado foi efetuado para o cátion 177Lu e para o [177Lu]-TPP. O complexo foi preparado com pureza radioquímica >97±1% e atividade específica de 970-1000 MBq/mmol. Os dados de biodistribuição e os resultados dosimétricos mostraram que todos os tecidos receberam uma dose absorvida aproximadamente insignificante devido à rápida excreção do complexo pelo trato urinário. O [177Lu]-TPP pode ser um agente interessante de direcionamento do tumor devido à baixa captação pelo fígado e pela dose bem baixa absorvida, de, aproximadamente, 0,036 do corpo humano total...
Subject(s)
Humans , Lutetium , Lutetium/administration & dosage , Lutetium/therapeutic use , Radioisotopes , Radioisotopes/administration & dosage , Radioisotopes/therapeutic use , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/therapeutic use , Porphyrins/administration & dosage , Porphyrins/therapeutic use , Uses of RadiationABSTRACT
OBJETIVO: Avaliar a dose absorvida em folículos tireoidianos devido aos elétrons de baixa energia, como oselétrons Auger e os de conversão interna, além das partículas beta, para os radioisótopos de iodo (131I, 132I,133I, 134I e 135I) usando o método Monte Carlo. MATERIAIS E MÉTODOS: O cálculo da dose foi feito ao nível folicular, simulando elétrons Auger, conversão interna e partículas beta, com o código MCNP4C. Os folículos (colóide e células foliculares) foram modelados como esferas, com diâmetros do colóide variando de 30 a 500 μm. A densidade considerada para os folículos foi a da água (1,0 g.cmû³). RESULTADOS: Considerando partículas de baixa energia, o percentual de contribuição do 131I na dose total absorvida pelo colóide é de aproximadamente 25%, enquanto os isótopos de meia-vida física curta apresentaram contribuição de 75%. Para as células foliculares, esse percentual é ainda maior, chegando a 87% para os iodos de meia-vida curtae 13% para o 131I. CONCLUSÃO: Com base nos resultados obtidos, pode-se mostrar a importância de se considerar partículas de baixa energia na contribuição para a dose total absorvida ao nível folicular (colóide e células foliculares) devido aos radioisótopos de iodo (131I, 132I, 133I, 134I e 135I).
OBJECTIVE: To evaluate the absorbed dose in thyroid follicles due to low-energy electrons such as Auger and internal conversion electrons, besides beta particles, for iodine radioisotopes (131I, 132I, 133I, 134I and 135I)utilizing the Monte Carlo method. MATERIALS AND METHODS: The dose calculation was performed at follicularlevel, simulating Auger, internal conversion electrons and beta particles, with the MCNP4C code. The follicles(colloid and follicular cells) were modeled as spheres with colloid diameter ranging from 30 to 500 μm, and with the same density of water (1.0 g.cmû³). RESULTS: Considering low-energy particles, the contributionof 131I for total absorbed dose to the colloid is about 25%, while the contribution due to short-lived isotopesis 75%. For follicular cells, this contribution is still higher achieving 87% due to short-lived iodine and 13%due to 131I. CONCLUSION: The results of the present study demonstrate the importance of considering lowenergyparticles in the contribution for the total absorbed dose at follicular level (colloid and follicular cells) due to iodine radioisotopes (131I, 132I, 133I, 134I and 135I).